TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Patients with Changes in Therapy or Device Programming
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Whole-body measurements of body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abdominal wall function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Xtampza ER during radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospitalizations and emergency room visits for COPD exacerbation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in veteran agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of peptic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in mean seated systolic blood pressure (MSSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immediate breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical resolution of local symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Device or Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Greater Than or Equals to (>=)50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Functional Independence Measure (TFIM) Change Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inspiratory pleural pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical evaluation of the transplanted area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving Functional Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPAx levels at three months after discharge from ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in LH and cortisol pulsatility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative drainage magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of upper respiratory infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline on ADAS-Cog13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV testing at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV testing at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Syphilis testing at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Syphilis testing at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Chlamydia and Gonorrhea testing at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hopkins Symptom Checklist (HSCL-Short form, 8 items)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Obesity BMI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response to TDaP-IPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell response to TDaP-IPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PBMC cytokine response to pertussis related antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of colonized catheters
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants Who Survived Without AIDS Progression
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of sodium-fluid disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Curve From 0 to ∞ Hours (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery Asberg depression rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease-control duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue changes in µm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vascular ultrasound variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: knowledge in approach to family medicine genetics
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: attitude towards family medicine genetics and genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: skill in discussing these issues with patients
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative castration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Presence/absence of rs6265 in the BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of 5-HTTLPR in the SLC6A4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic reactions to NSAIDs or opioid analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Body mass index exceeding 35
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Double Alpha Globin Deletions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of toenails attaining mycologic cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prosthetic prescription rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Use of prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trough R5 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Sentinel Lymph Node (SLN) Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: False Negative Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of True Positive SLN Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With Any Treatment-emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to the recommended regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change on International Trauma Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IOP Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independence level in self-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of participants with dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: negative mucosa potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who develop grade 3 or grade 4 haematological and gastrointestinal acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients who complete the planned chemoradiation protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of major radiotherapy protocol violations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline on the SF-36 Physical Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline on the SF-36 Mental Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in rectus femoris muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in mid-upper arm and calf circumferences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in triceps and biceps skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biochemical parameters related to muscle homeostasis, oxidative stress and inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Alanine transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Aspartate transaminase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Total Body protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Abnormal Laboratory Values and/or Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Autism Spectrum Quotient
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Serum 25OHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Scores for Criteria D Items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of sustained euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Performance on post-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline glycosylated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Venous Thrombo-Embolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Persistence or presence of Bifidobacterium Longum ssp longum AH1206
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of obstructive severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition age of early developmental skills (motor and language)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptive skills profile (Vineland adaptive behavioral scale)
Endpoint domain: Life impact
Endpoint subdomain: Functional outcomes
Primary endpoint: Bleeding prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency at 12-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom From Device and Procedure Related Target Limb Major Amputation or Death Through 30-days Post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Clinically-driven Target Lesion Revascularization at 12-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients achieving treatment success
Endpoint domain: Mortality/survival
Primary endpoint: Mechanical Pain Threshold after treatment at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile Threshold after treatment at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength after treatment at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local and distant failure
Endpoint domain: Mortality/survival
Primary endpoint: Change in bimanual hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day composite of death, stroke and myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: ipsilateral stroke at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Cmax of margetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of margetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of margetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of margetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Catheter Induced Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Chimerism in Unsorted Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chimerism in CD3+ Sorted Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AD libitum energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) or Adverse Drug Reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Serious Adverse Event (SAE) or Non-SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any New, Unexpected AE or Safety Signal
Endpoint domain: Adverse events/effects
Primary endpoint: Body Perception Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospitalized Anxiety and Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of new gadolinium CE T1 weighted lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Fruit and Vegetable Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Snack Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sugar-sweetened Beverage Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bioavailability of IP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma CoQ10 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pepsin concentration in tracheal aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vaccine-related Serious Adverse Experiences (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of DS-HB to predict difficult laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of analytes/protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of glycogen resynthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle functional recovery: Skeletal muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle functional recovery: Perceived muscle soreness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of Energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular Tolerability Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Peak Effect (Abolition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to >50% Diminution in Photo-Paroxysmal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin Autofluorescence Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Relative abundance and presence/absence of specific bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depressive and mental disorder episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IRLS rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects reporting local reactions within 14 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects reporting systemic events within 14 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects reporting serious adverse events within 6 months after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Olerud-Molander Ankle Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bilateral decrease of sensation to cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One Year Non-Relapse Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Ovarian Age prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Volume restoration in dorsal fingers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural history of disuse osteopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Transition to home dialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in White Formation Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Extent of White Spot Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Percentage of White Spot Lesion Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Developing RSV Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Autonomic Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway Distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants with Eradication of Helminthic and/or Protozoa
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients undergoing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Self-regulation skills for healthy eating and oral health
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-efficacy perception for healthy eating and oral health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Declarative Knowledge for Health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in caregiver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Narcotic Medication Usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 3-year Disease-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Symptomatic Venous Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Major and Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: lower internal mechanical strain in the soft tissue of the stump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Morning Peak Expiratory Flow (AM PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HIV-infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Multiple Sclerosis Spasticity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Albumin functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulatory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average total thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean echocardiographic score of pericardial effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of the anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospital Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Implant Crown Aesthetic Index (ICAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate at 3 months (complete and partial remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alberta Infant Motor Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satiety effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Acute Rejection Episodes
Endpoint domain: Adverse events/effects